Free Trial
NASDAQ:OLMA

Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis

Olema Pharmaceuticals logo
$4.50 -0.01 (-0.11%)
As of 12:24 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Olema Pharmaceuticals Stock (NASDAQ:OLMA)

Key Stats

Today's Range
$4.36
$4.58
50-Day Range
$3.06
$5.62
52-Week Range
$2.86
$16.62
Volume
179,347 shs
Average Volume
865,537 shs
Market Capitalization
$307.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.50
Consensus Rating
Buy

Company Overview

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Olema Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
57th Percentile Overall Score

OLMA MarketRank™: 

Olema Pharmaceuticals scored higher than 57% of companies evaluated by MarketBeat, and ranked 460th out of 924 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Olema Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Olema Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

  • Read more about Olema Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Olema Pharmaceuticals are expected to decrease in the coming year, from ($2.33) to ($2.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Olema Pharmaceuticals is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Olema Pharmaceuticals is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Olema Pharmaceuticals has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    11.76% of the float of Olema Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Olema Pharmaceuticals has a short interest ratio ("days to cover") of 5.7.
  • Change versus previous month

    Short interest in Olema Pharmaceuticals has recently decreased by 10.69%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Olema Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Olema Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.76% of the float of Olema Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Olema Pharmaceuticals has a short interest ratio ("days to cover") of 5.7.
  • Change versus previous month

    Short interest in Olema Pharmaceuticals has recently decreased by 10.69%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Olema Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Olema Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for OLMA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Olema Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.40% of the stock of Olema Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    91.78% of the stock of Olema Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Olema Pharmaceuticals' insider trading history.
Receive OLMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OLMA Stock News Headlines

Silver Demand Is Soaring-Supply Can't Keep Up
Silver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. Industrial demand is rising fast, but new supply isn't keeping pace. For investors, that opens the door to one key question: who already has it? One project in N. America just reported high-grade results at a time when ounces in the ground are becoming harder to find-and more valuable.
See More Headlines

OLMA Stock Analysis - Frequently Asked Questions

Olema Pharmaceuticals' stock was trading at $5.83 at the beginning of 2025. Since then, OLMA shares have decreased by 22.9% and is now trading at $4.4950.
View the best growth stocks for 2025 here
.

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) released its earnings results on Tuesday, May, 13th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.13.

Olema Pharmaceuticals (OLMA) raised $170 million in an initial public offering on Thursday, November 19th 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity served as the underwriters for the IPO.

Olema Pharmaceuticals' top institutional shareholders include Wellington Management Group LLP (2.16%), Candriam S.C.A. (1.24%), Charles Schwab Investment Management Inc. (0.51%) and Nuveen LLC (0.50%). Insiders that own company stock include Bain Capital Life Sciences Inv, Bvf Partners L P/Il, Biocapital Advisors L Paradigm, Cyrus Harmon, David C Myles, Sean Bohen and Naseem Zojwalla.
View institutional ownership trends
.

Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Olema Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

Last Earnings
5/13/2025
Today
5/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OLMA
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.50
High Stock Price Target
$30.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+444.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-96,650,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$4.61 per share
Price / Book
0.98

Miscellaneous

Free Float
46,182,000
Market Cap
$307.62 million
Optionable
Optionable
Beta
2.03
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:OLMA) was last updated on 5/15/2025 by MarketBeat.com Staff
From Our Partners